Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | F2R | P25116 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582811 | 1.00 | BCHE (0.41) | BCHETSHRALDH1A1PKMITGB3 | |
| SCHEMBL2600259 | 1.00 | BCHE (0.41) | BCHETSHRALDH1A1PKMITGB3 | |
| SCHEMBL26971791 | 0.83 | BCHE (0.56) | BCHETSHRALDH1A1PKMITGB3 | |
| SCHEMBL2600287 | 0.83 | BCHE (0.56) | BCHETSHRALDH1A1PKMITGB3 | |
| SCHEMBL13045996 | 0.80 | BCHE (0.43) | BCHETSHRALDH1A1PKMITGB3 | |
| SCHEMBL6991659 | 0.80 | ALDH1A1 (0.42) | BCHETSHRALDH1A1PKMITGB3 | |
| SCHEMBL3315913 | 0.80 | TSHR (0.62) | BCHETSHRITGB3ITGA2BF2R | |
| SCHEMBL2600258 | 0.79 | BCHE (0.39) | BCHETSHRALDH1A1PKMITGB3 | |
| SCHEMBL20837312 | 0.79 | MAPK8 (0.44) | ALDH1A1ITGB3ITGA2BLMNAMAPK1 | |
| SCHEMBL13999836 | 0.79 | BCHE (0.62) | BCHETSHRALDH1A1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452466-B1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10150760-B2 | Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor | AMGEN INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2018-08-09 | — | — | US | disclosed |
| US-9988369-B2 | Heterocyclic triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, GPR27 | BCHE 4453/4885TSHR 262/4885ALDH1A1 2981/4885 |
| US-10150760-B2 | Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor | TBXA2R, APLNR, GPR27 | BCHE 4453/4885TSHR 262/4885ALDH1A1 2981/4885 |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, AGTR1 | BCHE 4679/4885TSHR 225/4885ALDH1A1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.